Levi & Korsinsky notifies investors that it has commenced an investigation into Myriad Genetics, Inc. (NASDAQ: MYGN) concerning potential violations of the federal securities laws.
On October 31, 2024, it was revealed that UnitedHealth Group ("UnitedHealth") would no longer cover GeneSight, Myriad's genetic test to help determine which mental health medications are likely to work with an individual patient, beginning January 1, 2025. Specifically, market analysts reported that a document from UnitedHealth stated that the coverage is ending as tests for behavioral health, which includes GeneSight, are "unproven" and "not medically necessary." Following this news, Myriad's stock price fell over 18% on November 1, 2024.
If you suffered a loss on your Myriad Genetics, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





